FDA Antihypertensive Draft Class Labeling To Be Reviewed By Cardio-Renal Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s proposal for relabeling of antihypertensive agents is based on prior recommendations by the committee that information on cardiovascular outcomes related to blood pressure lowering be included as class labeling.